Imunon (IMNN) revenue and earnings history
Imunon's annual figures for 16 fiscal years, as filed with the SEC.
Over 5 years, from fiscal 2017 to fiscal 2022, revenue grew at a compound rate of 0.0% a year.
Revenue and net income, 16 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | — | −$14.7M | −$14.5M | −$13.9M | $281K | −$14.2M | $127K | — | — | $8.78M | — | 10-K |
| 2024ended Dec 31, 2024 | — |
The latest quarter, insider trades and fund moves: Imunon (IMNN) on OQRO.
Common questions
How fast has Imunon's revenue grown?
From $500K in fiscal 2017 to $500K in fiscal 2022: a compound annual growth rate of 0.0% over 5 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Imunon been profitable?
It reported a net loss in 16 of the years shown (2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$8.25M in fiscal 2013.
What was Imunon's free cash flow in fiscal 2025?
−$14.2M: operating cash flow of −$13.9M minus capital expenditure of $281K. OQRO calculates free cash flow this way from the two filed lines.
Where these figures come from
The SEC’s companyfacts data: every figure Imunon tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
